Comparison of 12-month courses of interferon-α-2b-lamivudine combination therapy and interferon-α-2b monotherapy among patients with untreated chronic hepatitis B

Clinical Infectious Diseases

Volumn 36, Issue 12, 2003, Pages 1516-1522

  Yalcin, Kendal ^a   Degertekin, Halil ^a   Yildiz, Fetin ^b   Celik, Yusuf ^a  

^a DICLE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b Diyarbakir Devlet Hastanesi   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA; ANTIVIRUS AGENT;

ADULT; ANOREXIA; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; HAIR LOSS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; MONOTHERAPY; MYALGIA; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT REDUCTION; XEROSTOMIA; ADOLESCENT; DRUG COMBINATION; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2B; LAMIVUDINE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 0037871938     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/375085     Document Type: Article

References (24)

1. Wong DKH, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1993; 119:312-23.
2. Hoofnagle JH, Peters M, Mullen KD, et al. Randomized, controlled trial of recombinant human-interferon in patients with chronic hepatitis B. Gastroenterology 1988; 95:1318-25.
3. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341:1236-63.
4. Lai CL, Chien RN, Leung NWY, et al. A one year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339:61-8.
5. Terrault NA. Combined interferon and lamivudine therapy: is this the treatment of choice for patients with chronic hepatitis B virus infection? Hepatology 2000; 32:675-7.
6. Mutimer D, Dowling D, Cane P, et al. Additive antiviral effects of lamivudine and alpha-interferon in chronic hepatitis B infection. Antivir Ther 2000; 5:273-7.
7. Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000; 46:562-8.
8. Barbaro G, Zechini F, Pellicelli AM, et al. Long term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B: an Italian multicenter, randomised trial. J Hepatol 2001; 35:406-11.
9. Mutimer D, Naoumov N, Honkoop P, et al. Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: results of a pilot study. J Hepatol 1998; 28:923-9.
10. Schiff ER, Karayalcin S, Grimm I, et al. A placebo controlled study of lamivudine and interferon alpha-2b in patients with chronic hepatitis B who previously failed interferon therapy [abstract]. Hepatology 1998; 28:388A.
11. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1:431-5.
12. Lok AS, Heathcote J, Hoofnagle J. Management of hepatitis B: 2000 - summary of a workshop. Gastroenterology 2001; 120:1828-53.
13. Schalm SW. Lamivudine-interferon combination therapy for chronic hepatitis B: further support but no conclusive evidence. J Hepatol 2001; 35:419-20.
14. Krogsgaard K, Christensen E, Bindslev N, Schalm SW, Andersen PK, Ring-Larsen H. Relation between treatment efficacy and cumulative dose of alpha interferon in chronic hepatitis B: the European Concerted Action on Viral Hepatitis (Eurohep). J Hepatol 1996; 25:795-802.
15. Janssen HLA, Gerken G, Carreno V, et al. Interferon alpha for chronic hepatitis B infection: increased efficacy of prolonged treatment. Hepatology 1999; 30:238-43.
16. Lok ASF, Wu PC, Lai CL, et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 1992; 102:2091-7.
17. Perillo RP, Schiff ER, Davis GL, et al. A randomised controlled trial of interferon alpha-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990; 323:295-301.
18. Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology 1989; 10:761-3.
19. Torresi J, Locarnini S. Antiviral chemotherapy for the treatment of hepatitis B virus infections. Gastroenterology 2000; 118(Suppl):S83-103.
20. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995; 13:29-60.
21. Boni C, Bertoletti A, Penna A, et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998; 102:968-75.
22. Boni C, Penna A, Ogg GS, et al. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 2001; 33:963-71.
23. Pichoud C, Berby F, Stuyver L, Petit MA, Trepo C, Zoulim F. Persistence of viral replication after anti-HBe seroconversion during antiviral therapy for chronic hepatitis B. J Hepatol 2000; 32:307-16.
24. Lampertico P, Del Ninno E, Manzin A, et al. A randomized controlled trial of a 24 month course of interferon alpha 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology 1997; 26:1621-5.